Mohanty Bibhu D, Mohanty Sudipta, Hussain Yasin, Padmaraju Chandrasekhar, Aggarwal Sameer, Gospin Rebekah, Yu Anthony F
Section of Cardiology, Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
Department of Medicine, University of California Riverside, Moreno Valley, CA 92555, USA.
Future Cardiol. 2017 May;13(3):247-257. doi: 10.2217/fca-2017-0002. Epub 2017 Jun 1.
Acute coronary syndrome (ACS) coinciding with active malignancy presents a unique clinical challenge given intersecting pathophysiology and treatment-related effects. There is little established clinical guidance on management strategies, rendering most treatment approaches anecdotal. We present a case highlighting the complexity of managing a patient being treated for malignancy who concurrently suffers from ACS. We then review the literature on co-management of ACS and malignancy, including reports of specific cancer therapies associated with ACS, unique features of clinical presentation and optimal use of dual antiplatelet therapy to minimize risks of bleeding and thrombosis. We also describe gaps in current literature, challenges in systematically studying the clinical intersection of these disease processes and propose alternative methodologies for further research.
急性冠状动脉综合征(ACS)与活动性恶性肿瘤同时存在,鉴于其相互交叉的病理生理学和治疗相关影响,带来了独特的临床挑战。关于管理策略,几乎没有既定的临床指南,这使得大多数治疗方法都只是 anecdotal(此处原文可能有误,推测是“ anecdotal”,意为轶事性的、缺乏科学依据的)。我们呈现一个病例,突出了管理一名正在接受恶性肿瘤治疗且同时患有 ACS 的患者的复杂性。然后,我们回顾了关于 ACS 和恶性肿瘤联合管理的文献,包括与 ACS 相关的特定癌症治疗报告、临床表现的独特特征以及双联抗血小板治疗的最佳使用,以将出血和血栓形成风险降至最低。我们还描述了当前文献中的空白、系统研究这些疾病过程临床交叉点的挑战,并提出了进一步研究的替代方法。